Thailand jumped from 1,093 kilograms to 20,658 in Australia’s latest trade table
Thailand shipped 20,658 kilograms of cannabis into Australia in 2025, up from 1,093 kilograms in 2024. Australia’s Office of Drug Control published the updated country-by-country table on 19 August 2026, and the jump moves Thailand into second place among Australia’s import sources, behind Canada at 49,107 kilograms.
That is a sharp shift, not a rounding error. Australia imported 81,119 kilograms of cannabis in total in 2025, so Thai product accounted for about a quarter of the inbound flow. One year earlier, Thailand was a minor line in the table. In the new data, it becomes part of the market’s main structure.
The timing matters because Australia was not short of licensed local output. The same federal dataset shows domestic production reached 55,337 kilograms in 2025. Year-end stock also finished high at 50,755 kilograms, made up of 29,366 kilograms of domestically cultivated product and 21,389 kilograms of imported product. In plain terms, more cannabis was being grown inside Australia, a large amount was still being brought in from abroad, and significant stock remained in the system at the end of the year.
That combination is what makes the Thailand number worth attention. A rise in imports can be easy to explain when local production is weak. It is harder to dismiss when domestic output is also rising. The new table suggests Australia’s regulated cannabis market is not simply filling a shortage. It is actively sourcing across borders even while local supply capacity expands.
That matters well beyond customs paperwork. Cultivators care because more imported product can weigh on price and contract security. Importers and wholesalers care because a new origin of scale changes purchasing options and supply concentration. Pharmacies and product suppliers care because country mix can alter product range, replacement costs, and delivery planning. Investors and policy watchers care because the data shows that local cultivation capacity does not automatically translate into local market share.
The number also stands out because Australia’s import sources have usually been discussed through the lens of Canada’s dominance. Canada is still the largest foreign supplier by a wide margin. But the new table shows that the story is no longer Canada and everyone else. Thailand has moved into the frame as a major origin in its own right.
Australia’s licence-and-permit system points to formal medical trade, not spillover
The first question behind a jump like this is simple: what kind of trade is it. The answer from the regulatory structure is that these are controlled legal movements into Australia’s medicinal cannabis system, not an informal spillover from Thailand’s wider cannabis politics.
Australia does not allow medicinal-cannabis imports to arrive casually. The federal import framework requires an annual licence and a permit for each individual consignment. The import application must identify the overseas exporter. In practical terms, that means every shipment sits inside a paper trail that names the parties, the product, and the movement approval. Whatever commercial story sits behind the 20,658-kilogram number, it passed through a system built to control who can import and what can enter.
The wider Australian infrastructure also supports that reading. The federal regulator publishes public lists of approved manufacturers and suppliers of medicinal cannabis products, as well as approved cultivators and producers inside Australia. Those lists matter because they show a standing legal channel on both sides of the local-versus-import equation. There are authorised businesses able to make, source, receive, and distribute product under a national framework. The Thai volumes did not arrive into a vacuum.
Thailand has formal export permission pathways as well. The Thai Food and Drug Administration publishes cannabis forms for production, import, export, sale, possession, and shipment-specific permissions under its narcotics control process. Its English-language guidance also references the ministerial rules governing licences to produce, import, export, sell, or possess cannabis within that system. The practical point is straightforward. Thailand has a documented route for lawful cannabis export, and Australia has a documented route for lawful cannabis import.
That does not mean the policy environment is simple. Thailand’s domestic cannabis debate has moved sharply over the past few years, and outside observers often reduce the whole country to headlines about liberalisation and retrenchment. The new Australian import figure cuts through that noise in one important respect. At least for the shipments counted in Australia’s 2025 table, Thai cannabis was able to move through formal regulatory channels into a tightly controlled medical market.
It is also important to be precise about what the Australian data does and does not say. The trade table gives weight by source country. It does not explain the commercial terms of sale, the price per kilogram, the product mix, the potency range, the form of the cannabis, or the identity of the companies involved. It does not say whether the Thai material displaced Canadian imports, displaced Australian-grown product, or met a separate slice of demand. It shows a volume shift, and it shows that the shift was large.
That distinction matters because trade data can tempt people into broad conclusions that it cannot carry on its own. The safe reading is not that Thailand has permanently redefined the market. The safe reading is that a very large amount of regulated cannabis entered Australia from Thailand in one year, through systems that require licences and shipment approvals on both sides.
Rising imports next to 55,337 kilograms of local output change the pressure on Australian operators
For Australian cultivators and producers, the difficult part of the new table is not just the Thailand increase by itself. It is the increase alongside domestic growth and high stock. Local production reached 55,337 kilograms in 2025. Year-end domestic stock was 29,366 kilograms. Those are not the numbers of a market with no local base. They are the numbers of a market that has built cultivation and manufacturing capability but still faces heavy competition from imports.
That puts pressure on a simple idea that has circulated through many medical cannabis markets: once local greenhouses and indoor sites are built, imports will fade into a temporary bridge. Australia’s 2025 data points the other way. Imports remain larger than domestic production on a weight basis, at 81,119 kilograms versus 55,337 kilograms. Thai product’s rise makes that contrast harder to ignore.
For importers and wholesalers, the Thai surge may be read more positively. A second large origin can reduce dependence on one dominant source country. Canada remains the main supplier, but Australia’s market no longer appears to rest on a single foreign pillar. More origin diversity can improve negotiating leverage, support portfolio breadth, and lower exposure to one country’s production cycle or shipping disruption.
For pharmacies and approved product suppliers, the effect is less visible but still real. These businesses need predictable inventory, acceptable lead times, and enough product variety to serve prescribers and patients within a regulated system. When a country suddenly becomes a major source, it suggests buyers found something useful there, whether that was price, capacity, compliance readiness, product characteristics, or some combination of the four. The current data cannot separate those factors, but the outcome is visible in the shipment weight.
For investors and corporate planners, the key lesson is structural rather than dramatic. Domestic capacity is not the same thing as domestic market capture. A cultivation site can be built, licensed, and harvesting, but still struggle to win orders if imported supply arrives at a better landed cost, in a preferred specification, or with more reliable availability. None of that is proven by the table alone. What is proven is that the market accepted a much larger quantity of Thai supply during 2025.
The stock numbers add another useful clue. Australia ended 2025 with 21,389 kilograms of imported cannabis still in stock. That means inbound supply was not merely racing through the system without residue. Imported product remained in inventory at year-end in material volume. Combined with 29,366 kilograms of domestic stock, this points to a market where both local and foreign supply were building up at the same time.
That matters because inventory changes behavior. When stock is high, buyers can push harder on price and contract terms. Sellers become more exposed to replacement risk. Products that are slow to move can tie up working capital. Operators with narrower margins feel that pressure first. A new large supply source, even if only for one year, can deepen those effects.
There is also a policy implication. Governments that support local medicinal cannabis industries often assume that licences and domestic investment will do some of the protective work on their own. Australia’s figures suggest that a regulated medical market can remain open to substantial foreign competition without any obvious contradiction in the rules. If the imported product is lawful, approved, and commercially attractive, local production alone does not block it.
Thailand’s rise looks significant, but the missing pieces are price, product type, and durability
The strongest reading of the new data is not that Australia has chosen Thailand over local cultivation in any final sense. It is that Australia’s regulated cannabis market has become more internationally contestable than some local producers may have hoped.
A country does not jump from 1,093 kilograms to 20,658 kilograms by accident. That kind of change usually means multiple things lined up at once: exporters able to supply at volume, Australian importers willing to contract, product capable of clearing regulatory checks, and logistics that functioned at commercial scale. The federal trade table does not narrate those decisions, but it records their result.
What it does not show is just as important. There is no country-by-country price data in the published table. There is no split showing how much of the Thai volume was directed to particular product categories. There is no indication of whether the surge came from a broad group of buyers or a small number of large contracts. There is no confirmation yet that 2025 marks a lasting realignment rather than a concentrated one-year event.
That uncertainty cuts both ways. It should restrain any claim that Thailand has permanently redrawn Australia’s supply map. But it should also restrain the opposite claim, that the number is a one-off curiosity with little consequence. In a regulated market, one year of heavy imports can reshape price expectations, procurement habits, and competitor assumptions even before a longer trend is established.
There is a broader market signal here. Australia’s medicinal cannabis system is no longer best understood as a local industry with some imported supplementation at the margins. The 2025 numbers describe something more exposed to cross-border competition. Canada remains the largest external supplier. Thailand has now become a serious second source. Domestic production is rising. Stocks are high. Those facts belong together.
For local growers, that is a harder landscape than a simple demand-growth story. For importers, it is a wider field of supply. For policymakers, it is evidence that legal medical cannabis trade can reorganise quickly when the regulatory routes exist on both sides. For anyone trying to read the direction of the market, the central fact is plain enough. Australia did not import more Thai cannabis because the system lacked rules. It imported more Thai cannabis through the rules.
That is the part likely to endure. The exact country ranking may change again. Specific contracts may come and go. Thailand’s own policy settings may continue to evolve. But once a tightly controlled medical market shows that it can absorb a new foreign source at this scale, the burden shifts to domestic suppliers to prove they can compete on price, reliability, and product fit without assuming the border will do that work for them.